NASDAQ:OVID Ovid Therapeutics (OVID) Stock Price, News & Analysis $1.02 -0.12 (-10.53%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.96▼$1.1250-Day Range$0.75▼$1.3052-Week Range$0.68▼$4.10Volume249,673 shsAverage Volume458,070 shsMarket Capitalization$72.39 millionP/E RatioN/ADividend YieldN/APrice Target$4.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ovid Therapeutics alerts: Email Address Ovid Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside360.8% Upside$4.70 Price TargetShort InterestHealthy1.37% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.49) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.67 out of 5 starsMedical Sector62nd out of 910 stocksPharmaceutical Preparations Industry23rd out of 426 stocks 4.4 Analyst's Opinion Consensus RatingOvid Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOvid Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ovid Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.37% of the float of Ovid Therapeutics has been sold short.Short Interest Ratio / Days to CoverOvid Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ovid Therapeutics has recently decreased by 24.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOvid Therapeutics does not currently pay a dividend.Dividend GrowthOvid Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOvid Therapeutics has received a 71.15% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for Epilepsy or seizures" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Ovid Therapeutics is -0.85. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Ovid Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for OVID on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows18 people have added Ovid Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ovid Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.30% of the stock of Ovid Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.24% of the stock of Ovid Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ovid Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ovid Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ovid Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ovid Therapeutics is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOvid Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ovid Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Ovid Therapeutics Stock (NASDAQ:OVID)Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Read More OVID Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OVID Stock News HeadlinesSeptember 4 at 2:24 AM | markets.businessinsider.comBTIG downgrades Athira Pharma (ATHA) to a HoldSeptember 1, 2024 | americanbankingnews.comHead to Head Survey: Mural Oncology (NASDAQ:MURA) vs. Ovid Therapeutics (NASDAQ:OVID)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 31, 2024 | finance.yahoo.comOvid Therapeutics Inc. (OVID)August 21, 2024 | msn.comEvidence Still Lacking for Iron Deficiency Screening, Supplementation in PregnancyAugust 19, 2024 | benzinga.comExpert Outlook: Ovid Therapeutics Through The Eyes Of 7 AnalystsAugust 19, 2024 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)August 18, 2024 | nz.finance.yahoo.comOvid Therapeutics Inc (1OT.SG)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 15, 2024 | markets.businessinsider.comBuy Rating Justified by Ovid Therapeutics’ Clinical Progress and Strong FinancialsAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Clinical Progress and Promising Neurological PipelineAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial OutlookAugust 14, 2024 | finanznachrichten.deOvid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | markets.businessinsider.comOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerAugust 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDAugust 2, 2024 | prnewswire.comOVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law FirmAugust 1, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDSee More Headlines Receive OVID Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OVID CUSIPN/A CIK1636651 Webwww.ovidrx.com Phone(646) 661-7661FaxN/AEmployees60Year Founded2014Price Target and Rating Average Stock Price Target$4.70 High Stock Price Target$8.00 Low Stock Price Target$1.20 Potential Upside/Downside+360.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,340,000.00 Net Margins-5,237.15% Pretax Margin-5,237.32% Return on Equity-33.40% Return on Assets-22.94% Debt Debt-to-Equity Ratio0.16 Current Ratio5.73 Quick Ratio5.73 Sales & Book Value Annual Sales$390,000.00 Price / Sales185.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book0.82Miscellaneous Outstanding Shares70,970,000Free Float61,509,000Market Cap$72.39 million OptionableOptionable Beta0.41 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jeremy Max Levin Ba Zoology (Age 71)Dphil, Mb Bchir, President, CEO & Chairman Comp: $1.03MMr. Jeffrey A. Rona (Age 56)Chief Business and Financial Officer Comp: $761.24kMr. Thomas Michael Perone J.D. (Age 59)M.B.A., General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $745.71kMr. Jason Tardio M.B.A. (Age 47)Chief Operating Officer Comp: $652.84kMr. Simon D. Kelner (Age 50)Chief Human Resources Officer Dr. Dirk Haasner (Age 59)Senior Vice President of Global Manufacturing & CMC QA Comp: $416.95kDr. Todd F. Baumgartner M.D.M.P.H., Senior Vice President of Regulatory AffairsDr. Julia Tsai Ph.D. (Age 49)Senior Vice President of Clinical Development Ms. Meg AlexanderChief Strategy OfficerDr. Manoj Malhotra M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXTherapeuticsMDNASDAQ:TXMDAtea PharmaceuticalsNASDAQ:AVIRAC ImmuneNASDAQ:ACIUAlimera SciencesNASDAQ:ALIMView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCBought 1,400,191 shares on 8/16/2024Ownership: 1.974%DCF Advisers LLCBought 22,020 shares on 8/13/2024Ownership: 0.059%Dimensional Fund Advisors LPSold 67,187 shares on 8/9/2024Ownership: 0.388%Renaissance Technologies LLCSold 15,600 shares on 8/9/2024Ownership: 0.199%Rhumbline AdvisersSold 12,851 shares on 8/1/2024Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions OVID Stock Analysis - Frequently Asked Questions How have OVID shares performed this year? Ovid Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, OVID shares have decreased by 68.3% and is now trading at $1.02. View the best growth stocks for 2024 here. How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings results on Tuesday, August, 13th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.34. The firm earned $0.17 million during the quarter, compared to analysts' expectations of $0.14 million. Ovid Therapeutics had a negative trailing twelve-month return on equity of 33.40% and a negative net margin of 5,237.15%. When did Ovid Therapeutics IPO? Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' top institutional investors include Driehaus Capital Management LLC (1.97%), FFT Wealth Management LLC (0.69%), Dimensional Fund Advisors LP (0.39%) and Bank of New York Mellon Corp (0.31%). Insiders that own company stock include Jeremy M Levin and Jason Tardio. View institutional ownership trends. How do I buy shares of Ovid Therapeutics? Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP) and SCYNEXIS (SCYX). This page (NASDAQ:OVID) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVID Stock Alerts